“When is Anduril going to IPO?” is the question Matt Milner’s “The Next Elon Musk” presentation deliberately leaves hanging in the air, and the honest answer is that no one outside the company knows. Palmer Luckey has not announced a date, a timeline, or a firm commitment to go public, and no registration has been filed. What we can do is separate what is confirmed from what is rumor, and explain what an IPO would actually look like when it does come. Our Anduril Industries IPO Date: What We Know explainer covers this in detail.
What Is Confirmed
The confirmed facts are thin but meaningful. Anduril is a private company that has raised money through private funding rounds, and its valuation is a private-market number reported in the tens of billions across recent rounds. It is winning real defense contracts, including a $250 million award for more than 500 Roadrunner drone interceptor systems, the IVAS headset program takeover from Microsoft, and Navy industrial-base investment tied to its Ghost Shark autonomous submarine. None of that, however, amounts to a public listing, and there is no filed S-1 or reserved ticker as of this writing.
What Is Rumor
Everything else is speculation. Luckey has at times spoken about wanting to keep Anduril independent and has expressed ambivalence about public markets, but ambivalence is not a date. Any specific timeline floated online, any “next quarter” or “next year” claim, is a guess dressed up as reporting. The presentation itself does not name an IPO date, because there is not one to name. It simply uses the possibility of a future IPO as the reason pre-IPO exposure is valuable now.
What an IPO Would Look Like
When Anduril does eventually go public, the sequence is well understood. It would first file a confidential draft registration with the Securities and Exchange Commission, then publish a public S-1, conduct a roadshow to set the price, and finally list shares on a major exchange under a new ticker. Only at that final step would ordinary investors be able to buy Anduril directly. Until then, the company’s shares stay locked up with its founder, employees, and venture backers.
The Only Current Backdoor
Until an IPO happens, the only purchasable way to get indirect exposure in a regular brokerage account is the free ticker Milner hands out: XOVR, the ERShares Private-Public Crossover ETF, which holds Anduril alongside roughly 30 other private companies such as SpaceX. Milner is candid about its limits, that Anduril is not in the fund’s top 10 holdings and private companies make up only about 15% of the fund. It is the “backdoor” the presentation sells, and it is real, but it is a diluted sliver rather than a direct stake. For the full backstory, see our XOVR Price: Tracking the Private-Public Crossover ETF article.
For the full teardown of the presentation and its claims, read our complete Next Elon review. For another angle on the pre-IPO theme, see our OXF AI IPO review, and for the broader defense-tech trade, see our AI defense stocks piece.
What to Watch For
If you want to track the IPO question yourself rather than rely on speculation, there are a few concrete signals to watch. The first is the SEC’s confidential filing system, since a company can file a draft registration privately before any public announcement, and the filing itself is not visible until the company chooses to reveal it. The second is funding-round news, because a fresh private round at a higher valuation tends to push an IPO further out, while a company that stops raising privately is often preparing for something public. The third is Luckey’s own public comments, which have at times leaned toward staying private. None of these signals gives you a date, and none of them can be read as a commitment, but together they tell you whether the window is opening or closing, and that is more useful than any single rumored timeline. Until one of those signals actually fires, the honest answer stays the same: no one outside the company knows, and the only exposure available today is the indirect kind the presentation sells.
Our Take
There is no confirmed Anduril IPO date, and treating the absence of one as a mystery is itself part of the pitch’s appeal. The honest takeaway is that the timeline is unknown and the company controls the decision, which means the pre-IPO framing is about optionality, not certainty. XOVR is the mechanism for indirect exposure today, and it is real and purchasable. Whether that diluted sliver satisfies you before any IPO arrives is the question the presentation hopes you will answer by subscribing. That is the real question, and it has no shortcut.
Ready to see the research? Click here to access Matt Milner’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.